Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile

Am J Transplant. 2004 Dec;4(12):2139; author reply 2140. doi: 10.1111/j.1600-6143.2004.00619.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / prevention & control
  • Cyclosporine / adverse effects*
  • Graft Rejection
  • Graft Survival / drug effects
  • Graft Survival / immunology*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / physiology
  • Quality of Life
  • Risk Factors
  • Tacrolimus / therapeutic use*

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Tacrolimus